levosulpiride

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Stem definition	Drug id	CAS RN
sulpiride derivatives and analogues	1577	23672-07-3

Stem definition

Drug id

CAS RN

sulpiride derivatives and analogues

1577

23672-07-3

Molecule	Description
Molfile Inchi Smiles Synonyms: levopraid levosulpiride (-)-Sulpiride L-Sulpiride lesuride levobren levopride	Molecular weight: 341.43 Formula: C15H23N3O4S CLOGP: 1.15 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 101.73 ALOGS: -2.80 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

levopraid
levosulpiride
(-)-Sulpiride
L-Sulpiride
lesuride
levobren
levopride

Molecular weight: 341.43
Formula: C15H23N3O4S
CLOGP: 1.15
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 101.73
ALOGS: -2.80
ROTB: 6

Dose	Unit	Route
0.40	g	O

Dose

Unit

Route

0.40

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK	24
kinase-selectivity-class	EIF2AK3,GRK2,PDK1,SIK2,TEK	5
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.476		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
rat-kpuu-brain	Rat brain Kpuu	0.012	%	High	1

Property

Description

Value

Unit

Confidence

Similarity

kinase-safety-class

ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK

kinase-selectivity-class

EIF2AK3,GRK2,PDK1,SIK2,TEK

mdck-mdr1-bcrp-efflux

MDCK-MDR1-BCRP efflux ratio

1.476

High

pfas-class

PFAS structural alert (1 = True, 0 = False)

rat-kpuu-brain

Rat brain Kpuu

0.012

High

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebellar syndrome	98.32	43.77	18	650	3854	90623925
Galactorrhoea	82.49	43.77	16	652	4656	90623123
Sopor	60.56	43.77	17	651	24627	90603152
Serotonin syndrome	57.50	43.77	18	650	37869	90589910
Hyperprolactinaemia	56.58	43.77	12	656	5421	90622358
Necrotising colitis	52.42	43.77	9	659	1329	90626450
Hyperthermia	48.90	43.77	12	656	10323	90617456
Blood lactic acid increased	45.65	43.77	11	657	8767	90619012

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Cerebellar syndrome

98.32

43.77

650

3854

90623925

Galactorrhoea

82.49

43.77

652

4656

90623123

Sopor

60.56

43.77

651

24627

90603152

Serotonin syndrome

57.50

43.77

650

37869

90589910

Hyperprolactinaemia

56.58

43.77

656

5421

90622358

Necrotising colitis

52.42

43.77

659

1329

90626450

Hyperthermia

48.90

43.77

656

10323

90617456

Blood lactic acid increased

45.65

43.77

657

8767

90619012

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disorganised speech	61.97	56.27	11	427	1417	42619480
Renal ischaemia	60.25	56.27	11	427	1659	42619238

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Disorganised speech

61.97

56.27

427

1417

42619480

Renal ischaemia

60.25

56.27

427

1659

42619238

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	109.51	42.81	32	1161	36514	110551592
Cerebellar syndrome	82.62	42.81	18	1175	6284	110581822
Galactorrhoea	78.19	42.81	16	1177	4139	110583967
Disorganised speech	57.93	42.81	12	1181	3291	110584815
Renal ischaemia	56.00	42.81	11	1182	2312	110585794
Drug abuse	52.05	42.81	29	1164	177382	110410724
Hyperprolactinaemia	49.70	42.81	12	1181	6563	110581543
Necrotising colitis	46.48	42.81	9	1184	1756	110586350
Serotonin syndrome	42.88	42.81	18	1175	59135	110528971

MedDRA adverse event term

Likelihood ratio

Likelihood ratio threshold

Patients taking drug having adverse event

Patients taking drug not having adverse event

Patients not taking drug having adverse event

Patients not taking drug not having adverse event

Sopor

109.51

42.81

1161

36514

110551592

Cerebellar syndrome

82.62

42.81

1175

6284

110581822

Galactorrhoea

78.19

42.81

1177

4139

110583967

Disorganised speech

57.93

42.81

1181

3291

110584815

Renal ischaemia

56.00

42.81

1182

2312

110585794

Drug abuse

52.05

42.81

1164

177382

110410724

Hyperprolactinaemia

49.70

42.81

1181

6563

110581543

Necrotising colitis

46.48

42.81

1184

1756

110586350

Serotonin syndrome

42.88

42.81

1175

59135

110528971

Source	Code	Description
ATC	N05AL07	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:50919	antiemetico

Source

Code

Description

ATC

N05AL07

NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Benzamides

CHEBI has role

CHEBI:35469

antidepressants

CHEBI has role

CHEBI:35476

neuroleptics

CHEBI has role

CHEBI:48561

dopaminergic antagonists

CHEBI has role

CHEBI:50919

antiemetico

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	acidic
pKa2	12.66	acidic
pKa3	8.85	Basic

Dissociation level

Dissociation constant

Type (acidic/basic)

pKa1

9.47

acidic

pKa2

12.66

acidic

pKa3

8.85

Basic

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	Ki	7.29	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	Ki	7.06	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	Ki	5.68	CHEMBL
Myeloperoxidase	Enzyme	P05164	PERM_HUMAN	IC50	5.12	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT	Ki	8.16	CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_BOVIN	Ki	4.30	CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT	IC50	6.68	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT	Ki	4.82	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT	Ki	4.57	CHEMBL

Target

Class

Pharos

UniProt

Action

Type

Activity value
(-log[M])

Mechanism
action

Bioact source

MoA source

D(2) dopamine receptor

GPCR

P14416

DRD2_HUMAN

7.29

CHEMBL

D(3) dopamine receptor

GPCR

P35462

DRD3_HUMAN

7.06

CHEMBL

D(4) dopamine receptor

GPCR

P21917

DRD4_HUMAN

5.68

CHEMBL

Myeloperoxidase

Enzyme

P05164

PERM_HUMAN

IC50

5.12

CHEMBL

D(2) dopamine receptor

GPCR

DRD2_RAT

8.16

CHEMBL

D(1A) dopamine receptor

GPCR

DRD1_BOVIN

4.30

CHEMBL

Dopamine receptor

GPCR

IC50

6.68

CHEMBL

Adrenergic receptor alpha-1

GPCR

ADA1B_RAT

ADA1D_RAT

ADA1A_RAT

4.82

CHEMBL

Serotonin 2 (5-HT2) receptor

GPCR

5HT2C_RAT

5HT2A_RAT

5HT2B_RAT

4.57

CHEMBL

External reference:

ID	Source
D07312	KEGG_DRUG
C0210380	UMLSCUI
CHEBI:64119	CHEBI
U6X	PDB_CHEM_ID
CHEMBL267044	ChEMBL_ID
DB16021	DRUGBANK_ID
C078143	MESH_SUPPLEMENTAL_RECORD_UI
688272	PUBCHEM_CID
6593	INN_ID
JTG7R315LK	UNII
018683	NDDF
1179629009	SNOMEDCT_US
702795007	SNOMEDCT_US
958	IUPHAR_LIGAND_ID
JTG7R315LK	INXIGHT DRUGS

Source

D07312

KEGG_DRUG

C0210380

UMLSCUI

CHEBI

PDB_CHEM_ID

ChEMBL_ID